Bibliography
- Woolf CJ ; American College of Physicians, American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann. Intern. Med.140 , 441 (2004).
- Bonica JJ . The management of pain. In: Bonica‘s Management of Pain (2nd Edition). Lea and Febiger, PA, USA (1990).
- Crombie IK , CroftPR, LintonSJ, LeRescheL, Von Korff M. Epidemiology of Pain. IASP Press, WA, USA (1999).
- LeResche L . Epidemiologic perspectives on sex differences in pain. In: Sex, Gender and Pain. Progress in Pain Research and Management (Volume 17). Fillingim RB (Ed.). IASP Press, WA, USA, 233–249 (2004).
- Maniadakis A , GrayA. The economic burden of back pain in the UK. Pain84 , 95–103 (2000).
- Waddell G , BurtonK, KendallN. Vocational Rehabilitation – What Works, For Whom and When? TSO, London, UK (2008).
- McBeth J , JonesK. Epidemiology of chronic musculoskeletal pain. Best Pract. Res. Clin. Rheumatol.21(3) , 403–425 (2007) .
- Linton SJ . A review of psychological risk factors in back and neck pain. Spine25(9) , 1148–1156 (2000).
- Melzack R , WallPD. Pain mechanisms: a new theory. Science150(699) , 971–979 (1965).
- Bhave G , GereauRW. Posttranslational mechanisms of peripheral sensitization. J. Neurobiol.61(1) , 88–106 (2004).
- Woolf CJ . Central sensitization: Implications for the diagnosis and treatment of pain. Pain152(Suppl. 3) , S2–S15 (2010).
- Dieppe P . Developments in osteoarthritis. Rheumatology50(2) , 245–247 (2011).
- Bajaj P , Graven-NielsenT, Arendt-NielsenL. Osteoarthritis and its association with muscle hyperalgesia: an experimental controlled study. Pain93 , 107–114 (2001).
- Dickenson AH . Spinal cord pharmacology of pain. Br. J. Anaesth.75(2) , 193–200 (1995)
- Dubner R , HargreavesKM. The neurobiology of pain and its modulation. Clin. J. Pain.5(2) , S1–S4; discussion S4–S6 (1989).
- Buskila D . Genetics of chronic pain states. Best Pract. Res. Clin. Rheumatol.21(3) , 535–547 (2007).
- Holliday J , NeogiKL, FelsonT et al. Neurotransmitter receptor gene polymorphisms are associated with widespread pain: findings from the first genome-wide association study of musculoskeletal pain. Arthritis Rheum. 62(Suppl. 10) , 836 (2010).
- Zhang W , JonesA, DohertyM. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann. Rheum. Dis.63 , 901–907 (2004).
- Wolfe F , ZhaoS, LaneN. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum.43(2) , 378–385 (2000).
- Leith JL , WilsonAW, DonaldsonLF, LumbBM. Cyclooxygenase-1-derived prostaglandins in the periaqueductal gray differentially control C- versus A-fibre-evoked spinal nociception. J. Neurosci.27(42) , 11296–11305 (2007).
- Crofford LJ . Adverse effects of chronic opioid therapy for chronic musculoskeletal pain. Nat. Rev. Rheumatol.6(4) , 191–197 (2010).
- Ilett KF , PaechMJ, Page-SharpM et al. Use of a sparse sampling study design to assess transfer of tramadol and its O-desmethyl metabolite into transitional breast milk. Br. J. Clin. Pharmacol. 65(5) , 661–666 (2008).
- Hollingshead J , DühmkeRM, CornblathDR. Tramadol for neuropathic pain. Cochrane Database Syst. Rev.3 , CD003726 (2006).
- Schug SA . The role of tramadol in current treatment strategies for musculoskeletal pain. Ther. Clin. Risk Manag.3(5) , 717–723 (2007).
- Goldenberg DL . Pharmacologic treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract. Res. Clin. Rheumatol.21 , 499–511 (2007).
- Goldenberg DL , BurckhardtC, CroffordL. Management of fibromyalgia syndrome. JAMA292 , 2388–2395 (2004).
- Carville SF , Arendt-NielsenS, BliddalH et al. EULAR evidence based recommendations for the management of fibromyalgia syndrome. Ann Rheum. Dis. 67 , 536–541 (2008).
- Goldenberg D , MayskiyM, MosseyC, RuthazerR, SchmidC. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum.39 , 1852–1859 (1996).
- Bardin L , GregoireS, AliagaM et al. Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. Neurosci. Res. 66 , 135–140 (2010).
- Jones CK , PetersSC, ShannonHE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J. Pharmacol. Exp. Ther.312 , 726–732 (2005).
- Arnold LM , LuY, CroffordLJ et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 50 , 2974–2984 (2004).
- Arnold LM , RosenA, PritchettYL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain119(1–3) , 5–15 (2005).
- Chappell AS , OssannaMJ, Liu-SeifertH et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo controlled trial. Pain 146 , 253–260 (2009).
- Crofford LJ , RowbothamMC, MeasePJ et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52 , 1264–1273 (2005).
- Arnold LM , GoldenbergDL, StanfordSB et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 56 , 1336–1344 (2007).
- Russell IJ , PerkinsAT, MichalekJE. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum.60(1) , 299–309 (2009).
- Korhonen T , KarppinenJ, PaimelaL, et al. The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. Spine30(24) , 2724–2728 (2005).
- Leung L , CahillCM. TNF-α and neuropathic pain – a review. J. Neuroinflammation7 , 27 (2010).
- Jhaveri MD , ElmesSJ, KendallDA, ChapmanV. Inhibition of peripheral vanilloid TRPV1 receptors reduces noxious heat-evoked responses of dorsal horn neurons in naïve, carrageenan-inflamed and neuropathic rats. Eur. J. Neurosci.22(2) , 361–370 (2005).
- Gunthorpe MJ , SzallasiA. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr. Pharm. Des.14(1) , 32–41 (2008).
- Gavva NR , TreanorJJ, GaramiA et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 136(1–2) , 202–210 (2008).
- McMahon S . NGF as a mediator of inflammatory pain. In: Neurotrophins and Sensory Neurons: Role in Development, Maintenance and Injury. McMahon S (Ed.). Royal Society, London, UK, 431–440 (1996).
- Lane NE , SchnitzerTJ, BirbaraC et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363 , 1521–1531 (2010).
- Zylka MJ . Pain-relieving prospects for adenosine receptors and ectonucleotidases Trends Mol. Med.17(4) , 188–196 (2011).
- Cox JJ , ReimannF, NicholasAK et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444 , 894–898 (2006).
- Eccleston C , WilliamsAC, MorleyS. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst. Rev.2 , CD007407 (2009).
- Fields HL , BasbaumAI. Central nervous system mechanisms of pain modulation. In: Textbook of Pain (4th Edition). Wall PD, Melzack R (Eds). Churchill Livingstone, London, UK, 310 (1999).
- Watkins LR , MaierSF. GLIA: a novel drug discovery target for clinical pain. Nat. Rev.Drug Discov.2 , 973–985 (2003).